Zymeworks Inc.(ZYME)

Description: Zymeworks Inc is a Canada-based clinical-stage biopharmaceutical company. The Company focuses on the discovery, development and commercialization of multifunctional biotherapeutics. The Company's ZymeCAD platform is for protein modeling and structure-guided protein engineering. The Company's platforms include Azymetric Platform, AlbuCORE Platform, EFECT Platform and Zymelink Conjugation Platform + Cytotoxins. The Company's lead product candidate, ZW25, is a bispecific antibody, which is being evaluated in an adaptive Phase I clinical trial. Its ZW33 is a bi-specific antibody that delivers a cytotoxic payload to cancers cells by binding to different epitopes (bi-paratopic targeting) of the overexpressed HER2 protein. It focuses on developing a pipeline of preclinical product candidates and discovery-stage programs in immuno-oncology and other therapeutic areas. It analyzes protein characteristics to develop the scope of protein engineering to tackle biological systems.

---

Keywords: Medicine Cancer Biopharmaceutical Immunology Immune System Monoclonal Antibodies Cancer Immunotherapy Antibody Glycoproteins Toxins Her2 Bispecific Monoclonal Antibody Biological Systems Protein Engineering

---

Home Page: www.zymeworks.com

ZYME Technical Analysis

114 East 4th Avenue
Vancouver, BC V5T 1G4
Canada
Phone: 604-678-1388

---

Officers

Exchange: NASDAQ

Country: US : United States of America

Currency: US Dollar ($)